poisar

Stock

Zevra Therapeutics, Inc. ZVRA

$9.51-1.35%

Overview

ZVRA market data

Price History

ZVRA price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
4.87
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$1.45
Diluted earnings per share over the trailing twelve months.
Beta
0.91
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$7.16 – $15.04
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $604.9 · P/B 3.26 · P/S 4.95.

Company News

10 captured
Canaccord Genuity Maintains Buy on Zevra Therapeutics, Lowers Price Target to $20Benzinga · Jul 27, 2026, 1:47 PM
Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24Benzinga · Jul 27, 2026, 12:57 PM
Ford To Rally Around 22%? Here Are 10 Top Analyst Forecasts For MondayBenzinga · Jul 27, 2026, 11:58 AM
BTIG Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24Benzinga · Jul 27, 2026, 10:05 AM
12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · Jul 24, 2026, 5:05 PM
Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type CBenzinga · Jul 24, 2026, 4:47 PM
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European UnionGlobenewswire Inc · Jul 24, 2026, 12:15 PM
Zevra Therapeutics shares are trading lower after the company announced the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency adopted a negative opinion regarding the Marketing Authorization Application for arimoclomol for the treatment of Niemann-Pick disease type C.Benzinga · Jul 24, 2026, 11:50 AM
Zevra Therapeutics Receives Negative Opinion From EMA CHMP On Its Marketing Authorization Application For Arimoclomol For The Treatment Of Niemann-Pick Disease Type CBenzinga · Jul 24, 2026, 11:33 AM
HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price TargetBenzinga · Jun 23, 2026, 4:40 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock